TCTC Holdings’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.5M Sell
388,238
-300
-0.1% -$17.5K 0.67% 41
2025
Q4
$21M Sell
388,538
-520
-0.1% -$25K 0.63% 42
2025
Q3
$17.5M Sell
389,058
-9,719
-2% -$454K 0.52% 44
2025
Q2
$18.5M Sell
398,777
-8,952
-2% -$439K 0.59% 42
2025
Q1
$24.9M Buy
407,729
+53
+0% +$3.09K 0.88% 32
2024
Q4
$23.1M Buy
407,676
+377
+0.1% +$21.1K 0.83% 31
2024
Q3
$21.1M Sell
407,299
-15,645
-4% -$734K 0.71% 39
2024
Q2
$17.6M Sell
422,944
-20,600
-5% -$922K 0.6% 40
2024
Q1
$24.1M Buy
443,544
+3,909
+0.9% +$199K 0.8% 36
2023
Q4
$22.6M Buy
439,635
+1,116
+0.3% +$58.6K 0.82% 33
2023
Q3
$25.5M Buy
438,519
+1,092
+0.2% +$66.9K 0.98% 26
2023
Q2
$28M Buy
437,427
+732
+0.2% +$49.1K 1.12% 23
2023
Q1
$30.3M Buy
436,695
+5,160
+1% +$364K 1.22% 18
2022
Q4
$31M Buy
431,535
+2,463
+0.6% +$186K 1.27% 17
2022
Q3
$30.5M Sell
429,072
-360
-0.1% -$26.1K 1.32% 16
2022
Q2
$33.1M Buy
429,432
+113
+0% +$8.61K 1.45% 17
2022
Q1
$31.4M Sell
429,319
-7,229
-2% -$485K 1.29% 18
2021
Q4
$27.2M Buy
436,548
+3,277
+0.8% +$192K 1.16% 20
2021
Q3
$25.6M Sell
433,271
-6,160
-1% -$406K 1.18% 21
2021
Q2
$29.4M Buy
439,431
+14,849
+3% +$968K 1.35% 19
2021
Q1
$26.8M Buy
424,582
+3,250
+0.8% +$202K 1.27% 21
2020
Q4
$26.1M Buy
421,332
+5,380
+1% +$331K 1.4% 20
2020
Q3
$25.1M Buy
415,952
+14,487
+4% +$872K 1.55% 20
2020
Q2
$23.6M Sell
401,465
-570
-0.1% -$34.1K 1.4% 18
2020
Q1
$22.4M Buy
402,035
+4,120
+1% +$252K 1.69% 16
2019
Q4
$25.5M Buy
397,915
+400
+0.1% +$22.9K 1.31% 16
2019
Q3
$20.2M Buy
397,515
+9,850
+3% +$463K 1.06% 23
2019
Q2
$17.6M Buy
387,665
+68,550
+21% +$3.19M 0.96% 28
2019
Q1
$15.2M Hold
319,115
0.82% 30
2018
Q4
$16.6M Buy
319,115
+400
+0.1% +$21.5K 0.93% 27
2018
Q3
$19.8M Hold
318,715
0.91% 25
2018
Q2
$17.6M Sell
318,715
-355
-0.1% -$19.2K 0.85% 27
2018
Q1
$20.2M Buy
319,070
+400
+0.1% +$25.7K 1.07% 24
2017
Q4
$19.5M Sell
318,670
-245
-0.1% -$15.3K 1.02% 25
2017
Q3
$20.3M Buy
318,915
+934
+0.3% +$54.5K 1.25% 24
2017
Q2
$17.7M Hold
317,981
1.21% 25
2017
Q1
$17.3M Sell
317,981
-200
-0.1% -$11K 1.06% 30
2016
Q4
$18.6M Sell
318,181
-3,280
-1% -$179K 1.13% 26
2016
Q3
$17.3M Buy
321,461
+2,880
+0.9% +$185K 1.27% 23
2016
Q2
$23.4M Buy
318,581
+216
+0.1% +$15.3K 1.59% 13
2016
Q1
$20.3M Sell
318,365
-500
-0.2% -$31.5K 1.28% 19
2015
Q4
$21.9M Hold
318,865
1.32% 14
2015
Q3
$18.9M Buy
318,865
+9,125
+3% +$579K 1.07% 19
2015
Q2
$20.6M Sell
309,740
-400
-0.1% -$26.4K 1.18% 16
2015
Q1
$20M Hold
310,140
1.18% 18
2014
Q4
$18.3M Hold
310,140
1.11% 22
2014
Q3
$15.9M Sell
310,140
-40
-0% -$2K 0.92% 27
2014
Q2
$15M Hold
310,180
0.95% 24
2014
Q1
$16.1M Sell
310,180
-1,400
-0.4% -$74.5K 0.93% 23
2013
Q4
$16.6M Buy
311,580
+600
+0.2% +$30.6K 0.95% 22
2013
Q3
$14.4M Hold
310,980
0.92% 23
2013
Q2
$13.9M Buy
+310,980
New +$13.5M 0.91% 23

Other funds holding BMY

TCTC Holdings's BMY Position: Q1 2026 in Review

TCTC Holdings reduced its Bristol-Myers Squibb (BMY) stake by 0.08% in Q1 2026, selling an estimated $17.5K and leaving 388,238 shares worth $23.5M. The position accounts for 0.67% of the portfolio, ranked #41.

TCTC Holdings first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $33.1M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • TCTC Holdings held 388,238 shares of Bristol-Myers Squibb worth $23.5M as of Q1 2026.
  • TCTC Holdings sold 300 Bristol-Myers Squibb shares in Q1 2026, an estimated $17.5K.
  • Bristol-Myers Squibb made up 0.67% of TCTC Holdings's portfolio in Q1 2026, its #41 holding.
  • TCTC Holdings first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • TCTC Holdings's Bristol-Myers Squibb position peaked at $33.1M in Q2 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on TCTC Holdings's 13F filing for Q1 2026, filed 7 May 2026.